GE has shifted its executive lineup in Asia, promoting Goran Malm to president of GE Asia-Pacific and naming Yoshiaki Fujimori to assume Malm's position as president and CEO of GE Medical Systems Asia. Fujimori was previously general manager of global
GE has shifted its executive lineup in Asia, promoting Goran Malm to president of GE Asia-Pacific and naming Yoshiaki Fujimori to assume Malm's position as president and CEO of GE Medical Systems Asia. Fujimori was previously general manager of global MRI, nuclear medicine, and PET at GE Medical Systems in Milwaukee.
Malm is credited with orchestrating the expansion of GEMS in a broad geographic region that ranges from Japan to Australia to India. In his new capacity, Malm will lead GE's international activities in the Asia-Pacific region.
Fujimori credited the MRI product development group's ability to bring new systems to market as a key to his elevation. This is Fujimori's second Asian tour of duty: He was manager of business development for GE Medical Systems Asia in 1990 when he was transferred to Milwaukee as general manager of nuclear medicine. In 1992, he was named manager of CT and radiation therapy. In February 1996, the company announced his appointment as global general manager of MRI operations.
Succeeding Fujimori as general manager of global MRI is Gene Saragnese, who was transferred to Milwaukee in late 1995 as manager of MR engineering. Fujimori's managerial duties over nuclear medicine and PET in Milwaukee were delegated to Sharon Banaszewski, who was promoted to general manager of the nuclear medicine/PET group.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.